Pakistan, 7 September 2021, Hafeez et al, Clinical and Applied Thrombosis/Hemostasis
We utilized the World Health Organization’s criteria for a confirmed and probable case of TTS following COVID-19 vaccination and conducted a systematic review and posthoc analysis using the PRISMA 2020 statement. Of the 175 studies identified, a total of 25 studies with 69 patients were included in this systematic review and post hoc analysis. Platelet nadir (P < .001), arterial or venous thrombi (χ2=41.911, P=.05), and chronic medical conditions (χ2=25.507, P =.041) were statistically associated with death.
The most commonly implicated vaccine and the dose was a single dose of AstraZeneca (ChAdOx1 nCoV 19) among 73.9% (n=51) of the included patients. Other vaccines and doses were one dose of Janssen
(Ad26.COV2.S) (n=12, 17.4%), one dose of Pfizer/ BioNTech (BNT162b2) (n=2, 2.9%), two doses of Pfizer/ BioNTech (BNT162b2) (n=2, 2.9%), and two doses of Moderna (mRNA-1273) (n=1, 1.4%) vaccines.